12:00 AM
Jan 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Allovectin-7: Phase II trial update

Vical Inc. (VICL), San Diego, Calif.
Product: Allovectin-7
Business: Cancer
Therapeutic category: Immune stimulation
Target: HLA-B7
Description: Gene encoding HLA-B7 mismatched transplantation antigen complexed with lipid...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >